Top

Published in:

Open Access 01-12-2013 | Research article

Oral intake of phenylbutyrate with or without vitamin D₃upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

Authors: Akhirunnesa Mily, Rokeya Sultana Rekha, S M Mostafa Kamal, Evana Akhtar, Protim Sarker, Zeaur Rahim, Gudmundur H Gudmundsson, Birgitta Agerberth, Rubhana Raqib

Published in: BMC Pulmonary Medicine | Issue 1/2013

Abstract

Background

We earlier showed that 4-phenylbutyrate (PB) can induce cathelicidin LL-37 expression synergistically with 1,25-dihydroxyvitamin D₃ in a lung epithelial cell line. We aimed to evaluate a therapeutic dose of PB alone or in combination with vitamin D₃ for induction of LL-37 expression in immune cells and enhancement of antimycobacterial activity in monocyte-derived macrophages (MDM).

Methods

Healthy volunteers were enrolled in an 8-days open trial with three doses of PB [250 mg (Group-I), 500 mg (Group-II) or 1000 mg (Group-III)] twice daily (b.d.) together with vitamin D₃ {5000 IU once daily (o.d.)}, PB (500 mg b.d.) (Group-IV) or vitamin D₃ (5000 IU o.d.) (Group-V), given orally for 4 days. Blood was collected on day-0, day-4 and day-8; plasma was separated, peripheral blood mononuclear cells (PBMC), non-adherent lymphocytes (NAL) and MDM were cultured. LL-37 transcript in cells and peptide concentrations in supernatant were determined by qPCR and ELISA, respectively. In plasma, 25-hydorxyvitamin D₃ levels were determined by ELISA. MDM-mediated killing of Mycobacterium tuberculosis (Mtb) (H37Rv) was performed by conventional culture method.

Results

MDM from Group-II had increased concentration of LL-37 peptide and transcript at day-4, while Group-I showed increased transcript at day-4 and day-8 compared to day-0 (p < 0.05). Both Group-I and -II exhibited higher levels of transcript on day-4 compared to Group-III and Group-V (p < 0.035). Increased induction of peptide was observed in lymphocytes from Group-II on day-4 compared to Group-I and Group-IV (p < 0.05), while Group-IV showed increased levels on day-8 compared to Group-I and Group-III (p < 0.04). Intracellular killing of Mtb on day-4 was significantly increased compared to day-0 in Group-I, -II and -V (p < 0.05).

Conclusion

The results demonstrate that 500 mg b.d. PB with 5000 IU o.d. vitamin D₃ is the optimal dose for the induction of LL-37 in macrophages and lymphocytes and intracellular killing of Mtb by macrophages. Hence, this dose has potential application in the treatment of TB and is now being used in a clinical trial of adults with active pulmonary TB (NCT01580007).

Available only for authorised users

Smith PE, Moss AR: Tuberculosis: pathogenesis, protection, and control, epidemiology of tuberculosis. Epidemiol Tuberc. 1994, 1: 47-60.

Parsons LM, Driscoll JR, Taber HW, Salfinger M: Drug resistance in tuberculosis. Infect Dis Clin North Am. 1997, 11 (4): 905-928. 10.1016/S0891-5520(05)70397-4.CrossRefPubMed

Bradford WZ, Daley CL: Multiple drug-resistant tuberculosis. Infect Dis Clin North Am. 1998, 12 (1): 157-172. 10.1016/S0891-5520(05)70415-3.CrossRefPubMed

Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH: HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010, 181 (1): 80-86. 10.1164/rccm.200907-0989OC.CrossRefPubMed

Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse IM, Andersen PL, Glerup H, Sodemann M: Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2009, 179 (9): 843-850. 10.1164/rccm.200804-567OC.CrossRefPubMed

Martins M: Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K + transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)–a novel, patentable approach to limit the emergence of XDR-TB. Recent Pat Antiinfect Drug Discov. 2011, 6 (2): 110-117. 10.2174/157489111796064524.CrossRefPubMed

Zasloff M: Antimicrobial peptides of multicellular organisms. Nature. 2002, 415 (6870): 389-395. 10.1038/415389a.CrossRefPubMed

Zaiou M, Gallo RL: Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med (Berl). 2002, 80 (9): 549-561. 10.1007/s00109-002-0350-6.CrossRef

Ganz T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003, 3 (9): 710-720. 10.1038/nri1180.CrossRefPubMed

10.

Kai-Larsen Y, Agerberth B: The role of the multifunctional peptide LL-37 in host defense. Front Biosci. 2008, 13: 3760-3767.CrossRefPubMed

11.

Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006, 311 (5768): 1770-1773. 10.1126/science.1123933.CrossRefPubMed

12.

Liu PT, Stenger S, Tang DH, Modlin RL: Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol. 2007, 179 (4): 2060-2063.CrossRefPubMed

13.

Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F: Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT study [supplementary cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect Dis. 2013, 13: 22-10.1186/1471-2334-13-22.CrossRefPubMedPubMedCentral

14.

Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ: A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007, 176 (2): 208-213. 10.1164/rccm.200701-007OC.CrossRefPubMed

15.

Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, Packe GE, Moore-Gillon JC, Darmalingam M, Davidson RN: High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011, 377 (9761): 242-250. 10.1016/S0140-6736(10)61889-2.CrossRefPubMedPubMedCentral

16.

Nnoaham KE, Clarke A: Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008, 37 (1): 113-119.CrossRefPubMed

17.

Raqib R, Sarker P, Bergman P, Ara G, Lindh M, Sack DA, Nasirul Islam KM, Gudmundsson GH, Andersson J, Agerberth B: Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc Natl Acad Sci U S A. 2006, 103 (24): 9178-9183. 10.1073/pnas.0602888103.CrossRefPubMedPubMedCentral

18.

Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B, Gudmundsson G: Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat Med. 2001, 7 (2): 180-185. 10.1038/84627.CrossRefPubMed

19.

Bergman P, Johansson L, Asp V, Plant L, Gudmundsson GH, Jonsson AB, Agerberth B: Neisseria gonorrhoeae downregulates expression of the human antimicrobial peptide LL-37. Cell Microbiol. 2005, 7 (7): 1009-1017. 10.1111/j.1462-5822.2005.00530.x.CrossRefPubMed

20.

Sarker P, Ahmed S, Tiash S, Rekha RS, Stromberg R, Andersson J, Bergman P, Gudmundsson GH, Agerberth B, Raqib R: Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. PLoS One. 2011, 6 (6): e20637-10.1371/journal.pone.0020637.CrossRefPubMedPubMedCentral

21.

Steinmann J, Halldorsson S, Agerberth B, Gudmundsson GH: Phenylbutyrate induces antimicrobial peptide expression. Antimicrob Agents Chemother. 2009, 53 (12): 5127-5133. 10.1128/AAC.00818-09.CrossRefPubMedPubMedCentral

22.

Yoshio H, Tollin M, Gudmundsson GH, Lagercrantz H, Jornvall H, Marchini G, Agerberth B: Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res. 2003, 53 (2): 211-216. 10.1203/00006450-200302000-00003.CrossRefPubMed

23.

Edfeldt K, Liu PT, Chun R, Fabri M, Schenk M, Wheelwright M, Keegan C, Krutzik SR, Adams JS, Hewison M: T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci U S A. 2010, 107 (52): 22593-22598. 10.1073/pnas.1011624108.CrossRefPubMedPubMedCentral

24.

Soliman MM, Ahmed MM, Salah-Eldin AE, Abdel-Aal AA: Butyrate regulates leptin expression through different signaling pathways in adipocytes. J Vet Sci. 2011, 12 (4): 319-323. 10.4142/jvs.2011.12.4.319.CrossRefPubMedPubMedCentral

25.

de Haan JB, Gevers W, Parker MI: Effects of sodium butyrate on the synthesis and methylation of DNA in normal cells and their transformed counterparts. Cancer Res. 1986, 46 (2): 713-716.PubMed

26.

Soliman M, Kimura K, Ahmed M, Yamaji D, Matsushita Y, Okamatsu-Ogura Y, Makondo K, Saito M: Inverse regulation of leptin mRNA expression by short- and long-chain fatty acids in cultured bovine adipocytes. Domest Anim Endocrinol. 2007, 33 (4): 400-409. 10.1016/j.domaniend.2006.08.005.CrossRefPubMed

27.

Kin NW, Chen Y, Stefanov EK, Gallo RL, Kearney JF: Cathelin-related antimicrobial peptide differentially regulates T- and B-cell function. Eur J Immunol. 2011, 41 (10): 3006-3016. 10.1002/eji.201141606.CrossRefPubMedPubMedCentral

28.

Agerberth B, Charo J, Werr J, Olsson B, Idali F, Lindbom L, Kiessling R, Jornvall H, Wigzell H, Gudmundsson GH: The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood. 2000, 96 (9): 3086-3093.PubMed

29.

Ottenhoff TH, Kaufmann SH: Vaccines against tuberculosis: where are we and where do we need to go?. PLoS Pathog. 2012, 8 (5): e1002607-10.1371/journal.ppat.1002607.CrossRefPubMedPubMedCentral

30.

Campbell GR, Spector SA: Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1. Autophagy. 2012, 8 (10): 1523-1525.CrossRefPubMedPubMedCentral

31.

Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo EK: Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe. 2009, 6 (3): 231-243. 10.1016/j.chom.2009.08.004.CrossRefPubMed

32.

Lee JS, Lee GM: Effect of sodium butyrate on autophagy and apoptosis in Chinese hamster ovary cells. Biotechnol Prog. 2012, 28 (2): 349-357. 10.1002/btpr.1512.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/13/23/prepub

Title: Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis
Authors: Akhirunnesa Mily
Rokeya Sultana Rekha
S M Mostafa Kamal
Evana Akhtar
Protim Sarker
Zeaur Rahim
Gudmundur H Gudmundsson
Birgitta Agerberth
Rubhana Raqib
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Pulmonary Medicine / Issue 1/2013
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/1471-2466-13-23

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Oral intake of phenylbutyrate with or without vitamin D₃upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

The association between asthma control, health care costs, and quality of life in France and Spain

Perseverant, non-indicated treatment of obese patients for obstructive lung disease

Noninvasive mechanical ventilation with average volume assured pressure support (AVAPS) in patients with chronic obstructive pulmonary disease and hypercapnic encephalopathy

Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment

Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study

The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page